FORWARD LOOKING STATEMENTS

This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements” within the meaning of applicable securities laws.

Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.

Such statements, risks and uncertainties are detailed in the Company’s ongoing filings with the securities regulatory authorities, and are available to the public at [www.sedar.com](http://www.sedar.com). The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Investment Summary

- **Financial growth**
  - Revenue expected to increase 250% to 4.4 million in 2019
  - Product gross margins >65% resulting in strong cash generation with sales growth

- **Strong customer base**
  - Customers include established diagnostics and global biopharma customers with strong qualified pipeline
  - Existing customer base includes imaware and University Health Network

- **Fully approved and commercializing**
  - SQI is continuing to commercialize their proprietary technologies and research and development to fuel their growth in clinical testing
  - Maximizing recurring revenue through the sale of consumable testing kits used with SQI testing instruments
What We Do?

SQI analyzes blood samples for multiple indications
### SQI Offering vs. Standard ELISA

SQI products save time and reduce costs, with superior technical performance offering 10 unique results per patient sample.

<table>
<thead>
<tr>
<th></th>
<th>Standard ELISA (semi-manual operation)</th>
<th>sqidlite™ (fully automated operation)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood Samples Required</strong></td>
<td>10 blood samples/patient</td>
<td>1 small blood sample/patient</td>
</tr>
<tr>
<td><strong>Duplicates</strong></td>
<td>20 if using duplicates</td>
<td>no duplicates needed</td>
</tr>
<tr>
<td><strong># of Kits</strong></td>
<td>20,180 ELISA Kits</td>
<td>1,042 SQI Kits</td>
</tr>
<tr>
<td><strong>Days of labour</strong></td>
<td>870 days of labour</td>
<td>34 days of labour on 2 sqidlites</td>
</tr>
<tr>
<td><strong>Time per patient</strong></td>
<td>50 minutes/patient</td>
<td>30 seconds/patient</td>
</tr>
</tbody>
</table>

10 biomarker panel 100,000 patient samples

ELISA - Enzyme-Linked Immunosorbent Assay is the commonly used form of blood testing.
SQI Revenues

SQI offers a full range of customized solutions to clinical diagnostic testing and testing for new drug development

- SQI offers state-of-the-art customized solutions that can be used in diagnostic testing for existing issues and testing for drug development
- SQI business model is based on driving recurring revenue by selling consumable testing kits used with SQI proprietary testing platforms

<table>
<thead>
<tr>
<th>Proprietary Instruments</th>
<th>Testing Kits</th>
<th>Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>• sqidworks™</td>
<td>• Custom diagnostics</td>
<td>• Rapid kit development</td>
</tr>
<tr>
<td>• Solution for high volume labs</td>
<td>• Custom pharma</td>
<td>• Pharma testing services</td>
</tr>
<tr>
<td>• sqidlite™</td>
<td>• FDA Cleared tests</td>
<td>• CLIA testing services</td>
</tr>
<tr>
<td>• Benchtop solution for mid-size facility</td>
<td>• Off the shelf biomarkers</td>
<td>• Co-development for specific indicators with industry thought leaders</td>
</tr>
<tr>
<td>• sqid-X™</td>
<td>• Drive Recurring Revenue</td>
<td></td>
</tr>
<tr>
<td>• Budget semi-automated solution</td>
<td>• Portable across instruments</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Revenue of up to $20/sample</td>
<td></td>
</tr>
</tbody>
</table>
## SQI Product Portfolio

The SQI product portfolio automates the clinical testing process to increase efficiencies up to 40%.

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Samples per year</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>sqidworks™</td>
<td>Ideal for high-volume labs, sqidworks runs three plates at a time, with just 30 minutes hands-on time.</td>
<td>FULLY AUTOMATED +150k SAMPLES / YR</td>
<td>$320k</td>
</tr>
<tr>
<td>sqidlite™</td>
<td>A practical benchtop workhorse that allows you to process one plate per run, after only 20 minutes setup.</td>
<td>FULLY AUTOMATED 75k-130k SAMPLES/YR</td>
<td>$220k</td>
</tr>
<tr>
<td>sqid-X™</td>
<td>Access all the multiplexing power of our Ig_plex technology on a budget, with our semi-automated system.</td>
<td>semi AUTOMATED 100k SAMPLES / YR</td>
<td>$90k</td>
</tr>
</tbody>
</table>
## SQI Existing Customers and Pipeline

SQI shift in focus from research and development to commercialization underway with a strong qualified pipeline

<table>
<thead>
<tr>
<th>Current Customers</th>
<th>Pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 consecutive quarters of growth in kit sales</td>
<td>Development of new at-home testing kits with existing and new partners</td>
</tr>
<tr>
<td>Strong existing customer base</td>
<td>Partnerships with industry thought leaders to support further</td>
</tr>
<tr>
<td>Partnerships with established pharma and diagnostic testing facilities</td>
<td>research and improvement in diagnostic testing</td>
</tr>
<tr>
<td></td>
<td>Large pharmaceutical companies that want to streamline testing for new</td>
</tr>
<tr>
<td></td>
<td>drug development</td>
</tr>
</tbody>
</table>

- UHN
- imaware
- PULS CARDIAC TEST
- BIOMARIN
- Brooklyn
- REGENERON
- Sunnybrook
- Genentech
- SQI DIAGNOSTICS
Strategy Overview

SQI offers a unique approach by combining research and development and commercialization aspects to testing

1. Toronto’s University Health Network partnership

   SQI entered an agreement to develop a new point-of-care diagnostic device and multiplex testing kit to assess the suitability of organs for transplantation resulting in immediate revenues of $1.1 million and high potential for recurring revenue upon completion

2. Organic growth

   SQI will focus on growth in existing kits and work with partners to develop new testing kits with a qualified pipeline that can more than double existing revenue

   Additional product development projects exist with current customers (UHN/imaware) that are incrementally much larger than current products being sold

3. CLIA test facility

   SQI is launching a fully integrated the testing service in the US with the establishment of a testing facility adding an incremental service-based revenue stream to kit sales, and increasing cash flow for each kit sold
The UHN Partnership will allow SQI to develop a solution that has the potential to be licensed internationally

- SQI and UHN are collaborating to develop a novel Lung Transplant test
- SQI will be developing a new point-of-care diagnostic device as well as kits and systems to complement the device
- Dr. Shaf Keshavjee of the University Health Network is an award-winning, world-renowned surgeon who specializes in lung transplants
- The research has the potential to be used not only to test lungs for transplants but also other organs in life-saving transplant operations
- Valued at $1.1 million in revenue over the next 12 months for services (excluding potential recurring revenue of ~$10K per patient)

Dr. Shaf Keshavjee
- The George Armstrong Peters Young Investigator Award
- Canada's Top 40 Under 40 Award
- The Colin Woolf Award for Excellence in Continuing Medical Education
- The Lister Prize in Surgery
- Inducted to Order of Canada
- Two Queen’s Jubilee medals
- Internationally recognized for Ex Vivo Lung Perfusion System
SQI has 6 consecutive quarters of growth in sales of diagnostic testing kits and pharmaceutical development testing kits

- SQI solutions provide significant opportunities for recurring revenue through the sale of diagnostic and new drug development testing kits
- SQI continues to establish new partnerships to develop new instruments and the accompanying kits that drive recurring revenue
- SQI pipeline includes global pharmaceutical companies and further penetration into the highly fragmented diagnostic testing center industry
Strategy Overview – CLIA Testing Facility

First SQI CLIA testing facility expected to be in production June 2019 to offer full service diagnostic testing to customers

- SQI is in the process of validating and establishing a CLIA-lab
  - CLIA: Clinical Laboratory Improvements Amendment

- Diagnostic testing centers prefer to spend time analyzing results not processing samples

- The new facility will fuel further top line growth through in-house testing of SQI kits

- Expected “in-production” date of Q3 2019, pending regulatory approval

- This one CLIA facility can consolidate nation-wide testing volume from all customers creating significant operating efficiencies

CLIA Testing Facility Location

Buffalo, NY
Through recurring revenue and qualified pipeline, SQI is positioned for strong growth in 2019.

Recurring Test Kit Revenue Forecast (C$ 000s)

- SQI has 3 distinct revenue streams:
  - Kit sales (recurring)
  - Instrument/platform sales
  - Service revenue for product development and CLIA testing services

~40% CAGR for Recurring Testing Kit Revenue
Key Performance Indicators

SQI is focused on increasing sales and optimizing margins through providing superior products and improving customer efficiencies.

Number of Testing Kit Sales (000s)

Gross Margin (%)

>65% Margin on Testing Kits

20% Revenue growth over past 6 quarters

$22 billion Untapped market size
Future Milestones and Execution

SQI is well positioned to supplement a commercialization aspect to their strong research expertise

- **CLIA Test Facility to Open**
  - June 2019

- **Completion of research phase of UHN partnership**
  - May 2020

- **RALI-DX product proof of concept**
  - June 2020

- **PULS FDA Clearance and widespread adoption**
  - 2H 2020

- **Kit sales equivalent to 1M samples per year**
  - 2023

**Notes**

RALI-DX: Rapid Acute Lung Injury Diagnostic test targeted at providing early diagnosis of Acute Respiratory Distress Syndrome

PULS FDA Clearance: SQI has transformed 7 of Predictive Health Diagnostics' 9 biomarkers for the PULS™ Cardiac Test (the "PULS Test") into an SQI-based multiplex test and is expecting FDA approval
Executive Team

SQI leadership team has vast experience ranging from corporate strategy and development to scientific expertise in biotechnology

Andrew Morris
Chief Executive Officer
Experience in corporate finance, corporate development and business strategy to lead the shift from research to commercialization.

Previous Experience:
- Ernst & Young
- allstream
- Scotiabank

Eric Brouwer
Chief Scientific Officer
Expertise in implementing market-leading technologies in FDA and ISO-regulated environments.

Previous Experience:
- Abbott
- Trinity Biotech
- Canada

Russ Peloquin
VP Sales and Marketing
Experience with biotechnology companies, leading high-level contract negotiations in the clinical diagnostics arena.

Previous Experience:
- Luminex

Patricia Lie
VP Finance
Over 20 years of financial and strategic management experience and holds CA and CFA designations.

Previous Experience:
- PwC
- TD

Aye Nyein San
VP Engineering
Over 10 years of experience in the medical device industry, with a breadth of experience and liquid handling systems.

Previous Experience:
- Baylis
- SGC
- University of Toronto

Peter Lea
Founder
Invented and patented the multiplexing microarray technology at the core of SQI Diagnostics.

Previous Experience:
- University of Toronto
- 45 Publications
- 40 Patents
Board of Directors

SQI Board of Directors own ~68% of the company and are aligned to maximize shareholder value

Clive J. Beddoe
Chair
*Affiliations:*
- WestJet
- Harborside
- The Canadian Business Hall of Fame

Gerald R. Connor
Board Member
*Affiliations:*
- Cumberland
- Allied

Wilmot L. Matthews
Board Member
*Affiliations:*
- BMO Nesbitt Burns

Claude Ricks
Board Member
*Affiliations:*
- AT Kearney
- Georgian
- SQI

Eric Schneider
Board Member
*Affiliations:*
- Miller Thomson
- SQI Diagnostics

Eric Zwisler
Board Member
*Affiliations:*
- Cardinal Health
- La Jolla Institute for Immunology

Andrew Morris
Board Member
*Affiliations:*
- SQI Diagnostics
SQI Diagnostics Inc. (TSXV:SQD) – Market Information

<table>
<thead>
<tr>
<th>Ticker:</th>
<th>TSX-V:SQD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traded on:</td>
<td>OTCQ:SQIDF</td>
</tr>
<tr>
<td>Shares Outstanding:</td>
<td>186.6 M</td>
</tr>
<tr>
<td>Market Cap:</td>
<td>~$28 M (May 2019)</td>
</tr>
</tbody>
</table>

SQI Diagnostics Inc. (TSXV:SQD) – Capital Structure

<table>
<thead>
<tr>
<th>Shareholders</th>
<th># of shares</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insiders</td>
<td>129,113,941</td>
<td>69.2%</td>
</tr>
<tr>
<td>Clive Beddoe/Hanover</td>
<td>41,515,238</td>
<td>22.2%</td>
</tr>
<tr>
<td>Wilmot Matthews/Marjad</td>
<td>41,500,197</td>
<td>22.2%</td>
</tr>
<tr>
<td>Gerald Connor/Cumberland</td>
<td>41,216,455</td>
<td>22.1%</td>
</tr>
<tr>
<td>Other Board Members</td>
<td>2,372,792</td>
<td>1.3%</td>
</tr>
<tr>
<td>Management</td>
<td>2,509,259</td>
<td>1.3%</td>
</tr>
<tr>
<td>Public Float</td>
<td>57,493,301</td>
<td>30.8%</td>
</tr>
<tr>
<td>Total Shares Outstanding</td>
<td>186,607,242</td>
<td>100%</td>
</tr>
</tbody>
</table>

SQI Diagnostics Inc. (TSXV:SQD) – Warrant Information

<table>
<thead>
<tr>
<th>Number of Warrants</th>
<th>Exercise Price</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>5,330,000</td>
<td>$0.64</td>
<td>July 16, 2020</td>
</tr>
<tr>
<td>3,560,000</td>
<td>$0.59</td>
<td>January 30, 2020 and February 20, 2020</td>
</tr>
<tr>
<td>7,631,000</td>
<td>$0.52</td>
<td>December 15 and 21, 2020</td>
</tr>
<tr>
<td>22,970,000</td>
<td>$0.21</td>
<td>March 10, 2022</td>
</tr>
<tr>
<td>463,000</td>
<td>$0.20</td>
<td>December 20, 2020</td>
</tr>
<tr>
<td>54,532,000</td>
<td>$0.20</td>
<td>December 20, 2022 – August 24, 2023</td>
</tr>
<tr>
<td>28,227,000</td>
<td>$0.11</td>
<td>March 1 and 8, 2024</td>
</tr>
<tr>
<td><strong>122,713,000</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SQI Diagnostics Inc. (TSXV:SQD) – Option Information

<table>
<thead>
<tr>
<th>Number of Options</th>
<th>Range of Exercise Prices</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,324,000</td>
<td>$0.14 – 0.25</td>
</tr>
<tr>
<td>1,972,000</td>
<td>$0.26 – 0.39</td>
</tr>
<tr>
<td>333,000</td>
<td>$0.40 – 0.60</td>
</tr>
<tr>
<td><strong>8,629,000</strong></td>
<td></td>
</tr>
</tbody>
</table>
Positive cash flow driven by high margin kits sales

## BLUE SKY OPPORTUNITY

### Annualized Recurring Revenue Potential

<table>
<thead>
<tr>
<th>Patient Samples tested per month</th>
<th>Clinical or Direct to Consumer Kits</th>
<th>CLIA Testing Services</th>
<th>TOTAL KIT REVENUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>10,000 --&gt;</td>
<td>$2,770,000</td>
<td>$2,400,000</td>
<td>$5,170,000</td>
</tr>
<tr>
<td>30,000 --&gt;</td>
<td>$7,480,000</td>
<td>$7,200,000</td>
<td>$14,680,000</td>
</tr>
<tr>
<td>2024 50,000 --&gt;</td>
<td>$11,220,000</td>
<td>$12,000,000</td>
<td>$23,220,000</td>
</tr>
</tbody>
</table>
Focus on Two Major Dx Markets

### Dx Target Markets Size Estimates 2017

<table>
<thead>
<tr>
<th>Market</th>
<th>Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global IVD Market</td>
<td>$59 billion</td>
</tr>
<tr>
<td>US IVD Market Total (2017)</td>
<td>$23 billion</td>
</tr>
<tr>
<td>Addressable Segments Estimate</td>
<td>20%</td>
</tr>
<tr>
<td>(Autoimmune, Cardiac, Inflammatory, Respiratory, Transplant, Other)</td>
<td></td>
</tr>
<tr>
<td>Clinical Dx Reagents (Kits) as % of Total Market</td>
<td>66%</td>
</tr>
</tbody>
</table>

### Addressable IVD Market for Kits

- $3.04 billion

### Direct to Consumer Kits

- $350 million

### Total

- $3.39 billion

### North America Biopharma

- Biopharma Drug Development Testing: $11 billion
- Reagents/Kits as % of Total Market: 66%
- Key SQI Addressable Segments (biomarkers, cytokines, immunogenicity): 33%

### Addressable Biopharma

- $2.40 billion

> $5 billion market in North America

6.6% CAGR
7 Plex panel for cardiac markers combined with a proprietary algorithm

Test predicts with 80% confidence likelihood of an adverse cardiac event forward for five years

Important as it provides forward-looking evidence to guide lifestyle changes or interventional treatment well ahead of an event

Customer currently running tests at their CLIA lab in California

SQI projected revenue to be ~$ 15.00 per test with volumes of 10,000 samples per month exiting Q4 2019

For more information go to www.pulstest.com
Direct to consumer strategy, large investment in on-line marketing, sales and fulfillment

2 sqidlites validated in Sept18

SQI’s celiac product launch Dec18

Followed by celiac monitoring subscription launched Jan19

SQI’s rheumatoid arthritis product Jan19

Follow-on products to be developed for imaware – cardiac health, men’s health, other....

A minimum number of kits to be purchased by imaware to maintain retail market exclusivity

Celiac Disease affects at least 3 million Americans. It is the most common — and one of the most underdiagnosed — hereditary autoimmune conditions in the United States today.

Rheumatoid Arthritis which afflicts 1% of the world’s population and where 1.3 million prescriptions will be written this year

For more information go to imaware.health
## Comparable Companies

Comparable figures are Last Quarter 2018 Annualized $,000s USD

<table>
<thead>
<tr>
<th>Company</th>
<th>Market Cap (,000s)</th>
<th>Revenue</th>
<th>Kit Revenue</th>
<th>Service Revenue</th>
<th>Price to sales</th>
<th>Gross Margin (kits)</th>
<th>Gross Margin (Service)</th>
<th>R&amp;D Expense</th>
<th>Operating Profit</th>
<th>Operating Cash Burn</th>
<th>Accumulated Deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACIFIC BIOSCIENCES</td>
<td>$ 1,200,000</td>
<td>$ 72,640</td>
<td>$ 60,600</td>
<td>$ 12,040</td>
<td>17x</td>
<td>19%</td>
<td>10%</td>
<td>$ 57,424</td>
<td>(98,680)</td>
<td>(109,524)</td>
<td>(951,000)</td>
</tr>
<tr>
<td>Quanterix</td>
<td>$ 545,000</td>
<td>$ 33,496</td>
<td>$ 20,800</td>
<td>$ 12,696</td>
<td>16x</td>
<td>43%</td>
<td>46%</td>
<td>$ 14,820</td>
<td>(29,244)</td>
<td>(76,832)</td>
<td>(167,000)</td>
</tr>
<tr>
<td>FLUIDIGM</td>
<td>$ 830,000</td>
<td>$ 116,000</td>
<td>$ 97,200</td>
<td>$ 18,800</td>
<td>7x</td>
<td>52%</td>
<td>68%</td>
<td>$ 29,720</td>
<td>(46,512)</td>
<td>(62,588)</td>
<td>(544,000)</td>
</tr>
<tr>
<td>Natera</td>
<td>$ 1,420,000</td>
<td>$ 261,120</td>
<td>$ 248,000</td>
<td>-</td>
<td>5x</td>
<td>37%</td>
<td>0%</td>
<td>$ 52,000</td>
<td>(108,664)</td>
<td>(117,992)</td>
<td>(542,688)</td>
</tr>
<tr>
<td>T2Biosystems</td>
<td>$ 115,000</td>
<td>$ 9,864</td>
<td>$ 4,872</td>
<td>$ 4,992</td>
<td>12x</td>
<td>neg</td>
<td>$ 10,900</td>
<td>(43,068)</td>
<td>(51,244)</td>
<td>(302,022)</td>
<td></td>
</tr>
<tr>
<td>Myriad</td>
<td>$ 2,068,000</td>
<td>$ 808,000</td>
<td>$ 756,000</td>
<td>$ 53,200</td>
<td>3x</td>
<td>32%</td>
<td>38%</td>
<td>$ 84,000</td>
<td>4,800</td>
<td>(18,800)</td>
<td></td>
</tr>
<tr>
<td>GenMark Dx</td>
<td>$ 415,000</td>
<td>$ 62,852</td>
<td>$ 62,852</td>
<td>-</td>
<td>7x</td>
<td>9%</td>
<td>0</td>
<td>$ 29,343</td>
<td>(49,547)</td>
<td>(39,947)</td>
<td>(455,000)</td>
</tr>
<tr>
<td>Averages</td>
<td>$ 941,857</td>
<td>$ 194,853</td>
<td>$ 178,618</td>
<td>$ 14,533</td>
<td>9x</td>
<td>32%</td>
<td>27%</td>
<td>$ 39,744</td>
<td>(52,988)</td>
<td>(68,132)</td>
<td>(493,618)</td>
</tr>
<tr>
<td>SQI Diagnostics</td>
<td>$ 21,374</td>
<td>$ 1,719</td>
<td>$ 800</td>
<td>$ 1100</td>
<td>12x</td>
<td>&gt;65%</td>
<td>90%</td>
<td>$ 4,410</td>
<td>(5,952)</td>
<td>(6,605)</td>
<td>(86,000)</td>
</tr>
</tbody>
</table>
CONTACT INFORMATION:

SQI DIAGNOSTICS INC.
36 METEOR DRIVE
TORONTO, CANADA  M9W 1A4
ir@sqidiagnostics.com/amorris@sqidiagnostics.com
416-674-9500 /X229